| Nov 12 |
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
|
| Nov 7 |
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report
|
| Nov 6 |
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully
|
| Nov 4 |
Foghorn Therapeutics GAAP EPS of -$0.31 beats by $0.13, revenue of $7.81M beats by $0.8M
|
| Nov 4 |
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 4 |
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
|
| Oct 23 |
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
|
| Oct 11 |
Foghorn Therapeutics Unveils Clinical Pipeline Progress
|
| Oct 10 |
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
|
| Oct 7 |
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
|
